Reference : SGLT2 Inhibitors: Benefit/Risk Balance.
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/203698
SGLT2 Inhibitors: Benefit/Risk Balance.
English
Scheen, André mailto [Université de Liège > Département des sciences cliniques > Département des sciences cliniques >]
2016
Current Diabetes Reports
16
10
92
Yes (verified by ORBi)
International
1534-4827
1539-0829
United States
[en] Cardiovascular disease ; Gliflozin ; Kidney ; SGLT2 inhibitor ; Type 2 diabetes mellitus
[en] Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycemia by increasing urinary glucose excretion. They have been evaluated in patients with type 2 diabetes treated with diet/exercise, metformin, dual oral therapy or insulin. Three agents are available in Europe and the USA (canagliflozin, dapagliflozin, empagliflozin) and others are commercialized in Japan or in clinical development. SGLT2 inhibitors reduce glycated hemoglobin, with a minimal risk of hypoglycemia. They exert favorable effects beyond glucose control with consistent body weight, blood pressure, and serum uric acid reductions. Empagliflozin showed remarkable reductions in cardiovascular/all-cause mortality and in hospitalization for heart failure in patients with previous cardiovascular disease. Positive renal outcomes were also shown with empagliflozin. Mostly reported adverse events are genital mycotic infections, while urinary tract infections and events linked to volume depletion are rather rare. Concern about a risk of ketoacidosis and bone fractures has been recently raised, which deserves caution and further evaluation.
http://hdl.handle.net/2268/203698
10.1007/s11892-016-0789-4

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
2016 curr Diab Ref SGLT2 Inhibitors Benefit Risk Balance.pdfPublisher postprint1.2 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.